Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
CymaBay files $200M mixed securities shelf  17:50
07/02/20
07/02
17:50
07/02/20
17:50
CBAY

CymaBay

$3.50 /

-0.06 (-1.69%)

 
ShowHide Related Items >><<
CBAY CymaBay
$3.50 /

-0.06 (-1.69%)

CBAY CymaBay
$3.50 /

-0.06 (-1.69%)

06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
06/22/20 B. Riley FBR
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR
05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
CBAY CymaBay
$3.50 /

-0.06 (-1.69%)

CBAY CymaBay
$3.50 /

-0.06 (-1.69%)

CBAY CymaBay
$3.50 /

-0.06 (-1.69%)

Tuesday
Recommendations
Intercept selloff yesterday overdone, says B. Riley FBR » 08:45
06/30/20
06/30
08:45
06/30/20
08:45
ICPT

Intercept

$46.64 /

-30.92 (-39.87%)

, GNFT

Genfit

$5.58 /

+0.01 (+0.18%)

, CBAY

CymaBay

$3.57 /

-0.175 (-4.68%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani lowered the firm's price target on Intercept Pharmaceuticals (ICPT) to $97 from $158 and keeps a Buy rating on the shares. The selloff yesterday on the unexpected receipt of a Complete Response Letter for obeticholic acid is overdone, Mamtani tells investors in a research note. With a large share of the FDA's infrastructure diverted towards COVID-19 drug development, it is reasonable for the agency to take more time in gaining comfort with obeticholic acid's clinical profile as well as histology-based surrogate endpoint that has recently been "muddled" by Genfit's (GNFT) Phase III unusually high placebo response and CymaBay's (CBAY) Phase II study challenged by errors in biopsy reads, says the analyst. Mamtani's long-term view remains favorable on approvability of obeticholic acid in nonalcoholic steatohepatitis.

ShowHide Related Items >><<
ICPT Intercept
$46.64 /

-30.92 (-39.87%)

GNFT Genfit
$5.58 /

+0.01 (+0.18%)

CBAY CymaBay
$3.57 /

-0.175 (-4.68%)

ICPT Intercept
$46.64 /

-30.92 (-39.87%)

06/30/20 Baird
Intercept downgraded to Neutral following "surprise" FDA decision at Baird
06/30/20 BMO Capital
Intercept downgraded to Market Perform from Outperform at BMO Capital
06/30/20 UBS
Intercept downgraded to Neutral from Buy at UBS
06/30/20 Credit Suisse
Intercept downgraded to Neutral from Outperform at Credit Suisse
GNFT Genfit
$5.58 /

+0.01 (+0.18%)

06/25/20 BofA
Genfit's NASH program 'all but done,' says BofA, initiating with an Underperform
06/25/20 BofA
Genfit initiated with an Underperform at BofA
05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
CBAY CymaBay
$3.57 /

-0.175 (-4.68%)

06/22/20 B. Riley FBR
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR
05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
ICPT Intercept
$46.64 /

-30.92 (-39.87%)

CBAY CymaBay
$3.57 /

-0.175 (-4.68%)

GNFT Genfit
$5.58 /

+0.01 (+0.18%)

ICPT Intercept
$46.64 /

-30.92 (-39.87%)

GNFT Genfit
$5.58 /

+0.01 (+0.18%)

CBAY CymaBay
$3.57 /

-0.175 (-4.68%)

Monday
On The Fly
Fly Intel: Pre-market Movers » 09:18
06/29/20
06/29
09:18
06/29/20
09:18
COTY

Coty

$4.18 /

-0.18 (-4.13%)

, BA

Boeing

$169.91 /

-5 (-2.86%)

, LCA

Landcadia

$10.12 /

+ (+0.00%)

, ALT

Altimmune

$10.60 /

+1.43 (+15.59%)

, FB

Facebook

$215.86 /

-19.73 (-8.37%)

, TWTR

Twitter

$29.05 /

-2.32 (-7.40%)

, DRRX

Durect

$2.42 /

-0.32 (-11.68%)

, BYND

Beyond Meat

$141.68 /

-3.58 (-2.46%)

, ICPT

Intercept

$77.56 /

-2.09 (-2.62%)

, CBAY

CymaBay

$3.74 /

-0.11 (-2.86%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$29.05 /

-2.32 (-7.40%)

LCA Landcadia
$10.12 /

+ (+0.00%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

FB Facebook
$215.86 /

-19.73 (-8.37%)

DRRX Durect
$2.42 /

-0.32 (-11.68%)

COTY Coty
$4.18 /

-0.18 (-4.13%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

BYND Beyond Meat
$141.68 /

-3.58 (-2.46%)

BA Boeing
$169.91 /

-5 (-2.86%)

ALT Altimmune
$10.60 /

+1.43 (+15.59%)

COTY Coty
$4.18 /

-0.18 (-4.13%)

05/13/20 Exane BNP Paribas
Coty downgraded to Neutral from Outperform at Exane BNP Paribas
05/13/20 Exane BNP Paribas
Coty downgraded to Neutral from Outperform at Exane BNP Paribas
05/12/20 Deutsche Bank
Coty price target lowered to $6 from $8 at Deutsche Bank
04/27/20
Coty cut to Neutral at DA Davidson on valuation
BA Boeing
$169.91 /

-5 (-2.86%)

06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
06/26/20 Bernstein
Boeing downgraded to Market Perform from Outperform at Bernstein
06/25/20
Fly Intel: Top five analyst downgrades
LCA Landcadia
$10.12 /

+ (+0.00%)

ALT Altimmune
$10.60 /

+1.43 (+15.59%)

06/01/20 Roth Capital
Altimmune surprises with differentiated T-COVID study, says Roth Capital
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
FB Facebook
$215.86 /

-19.73 (-8.37%)

06/29/20 JPMorgan
Facebook estimates not at risk from ad boycott, says JPMorgan
06/25/20 Baird
Facebook price target raised to $300 from $240 at Baird
06/24/20 Goldman Sachs
Facebook price target raised to $265 from $250 at Goldman Sachs
06/18/20 Morgan Stanley
Section 230 change likely a multi-year process, says Morgan Stanley
TWTR Twitter
$29.05 /

-2.32 (-7.40%)

06/22/20 Citi
Twitter price target raised to $36 from $30 at Citi
06/16/20 JPMorgan
JPMorgan continues to prefer Facebook, Snap in online advertising
DRRX Durect
$2.42 /

-0.32 (-11.68%)

06/29/20 B. Riley FBR
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
05/27/20 B. Riley FBR
Durect NASH data make 'strong case' for Phase II, says B. Riley FBR
05/27/20 H.C. Wainwright
H.C. Wainwright ups Durect target to $6 on positive NASH data
BYND Beyond Meat
$141.68 /

-3.58 (-2.46%)

06/29/20 Barclays
Barclays double downgrades Beyond Meat to Underweight on restaurant closures
06/29/20 Barclays
Beyond Meat downgraded to Underweight from Overweight at Barclays
06/17/20 Credit Suisse
Beyond Meat price target raised to $142 from $90 at Credit Suisse
06/17/20 Credit Suisse
Beyond Meat price target raised to $142 from $90 at Credit Suisse
ICPT Intercept
$77.56 /

-2.09 (-2.62%)

06/29/20 Wells Fargo
Intercept downgraded to Equal Weight at Wells Fargo on CRL for OCA in NASH
06/29/20 Wells Fargo
Intercept downgraded to Equal Weight from Overweight at Wells Fargo
06/29/20 Stifel
Intercept's accelerated approval in NASH at risk after CRL, says Stifel
06/25/20 H.C. Wainwright
Intercept initiated with a Neutral at H.C. Wainwright
CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

06/22/20 B. Riley FBR
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR
05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
TWTR Twitter
$29.05 /

-2.32 (-7.40%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

FB Facebook
$215.86 /

-19.73 (-8.37%)

DRRX Durect
$2.42 /

-0.32 (-11.68%)

COTY Coty
$4.18 /

-0.18 (-4.13%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

BYND Beyond Meat
$141.68 /

-3.58 (-2.46%)

BA Boeing
$169.91 /

-5 (-2.86%)

ALT Altimmune
$10.60 /

+1.43 (+15.59%)

  • 01
    Aug
TWTR Twitter
$29.05 /

-2.32 (-7.40%)

FB Facebook
$215.86 /

-19.73 (-8.37%)

DRRX Durect
$2.42 /

-0.32 (-11.68%)

COTY Coty
$4.18 /

-0.18 (-4.13%)

BYND Beyond Meat
$141.68 /

-3.58 (-2.46%)

BA Boeing
$169.91 /

-5 (-2.86%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

FB Facebook
$215.86 /

-19.73 (-8.37%)

DRRX Durect
$2.42 /

-0.32 (-11.68%)

COTY Coty
$4.18 /

-0.18 (-4.13%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

BYND Beyond Meat
$141.68 /

-3.58 (-2.46%)

BA Boeing
$169.91 /

-5 (-2.86%)

ALT Altimmune
$10.60 /

+1.43 (+15.59%)

TWTR Twitter
$29.05 /

-2.32 (-7.40%)

FB Facebook
$215.86 /

-19.73 (-8.37%)

DRRX Durect
$2.42 /

-0.32 (-11.68%)

COTY Coty
$4.18 /

-0.18 (-4.13%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

BYND Beyond Meat
$141.68 /

-3.58 (-2.46%)

BA Boeing
$169.91 /

-5 (-2.86%)

ALT Altimmune
$10.60 /

+1.43 (+15.59%)

Hot Stocks
Intercept plunges, drags down some NASH peers after CRL from FDA » 07:26
06/29/20
06/29
07:26
06/29/20
07:26
ICPT

Intercept

$77.56 /

-2.09 (-2.62%)

, CBAY

CymaBay

$3.74 /

-0.11 (-2.86%)

, NGM

NGM Biopharmaceuticals

$22.37 /

-0.53 (-2.31%)

, MDGL

Madrigal Pharmaceuticals

$108.04 /

-2.46 (-2.23%)

, NVO

Novo Nordisk

$66.03 /

-1.18 (-1.76%)

, GNFT

Genfit

$5.57 /

-0.42 (-7.01%)

, LLY

Eli Lilly

$162.91 /

-0.09 (-0.06%)

, ALNY

Alnylam

$151.68 /

-4.765 (-3.05%)

Shares of Intercept…

Shares of Intercept Pharmaceuticals (ICPT) have plunged in early morning trading after the company announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for obeticholic acid for the treatment of fibrosis due to nonalcoholic steatohepatitis, or NASH. Based on the data the FDA has reviewed to date, the Agency has determined that the predicted benefit of OCA based on a surrogate histopathologic endpoint remains uncertain and does not sufficiently outweigh the potential risks to support accelerated approval for the treatment of patients with liver fibrosis due to NASH, Intercept tells investors. Following the announcement, shares of Intercept are down $25.82, or 33%, to $51.67 in pre-market trading. A number of other companies working on NASH treatments are also moving lower, with CymaBay (CBAY) down about 3% and NGM Biopharmaceuticals (NGM) fractionally lower. Other companies exploring NASH treatments include Madrigal Pharmaceuticals (MDGL), Novo Nordisk (NVO), Genfit (GNFT), Eli Lilly (LLY), and Alnylam Pharmaceuticals (ALNY).

ShowHide Related Items >><<
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

GNFT Genfit
$5.57 /

-0.42 (-7.01%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

06/25/20 H.C. Wainwright
Intercept initiated with a Neutral at H.C. Wainwright
06/04/20 BMO Capital
Intercept initiated with an Outperform at BMO Capital
05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

06/22/20 B. Riley FBR
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR
05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

06/04/20 BMO Capital
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital
05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
GNFT Genfit
$5.57 /

-0.42 (-7.01%)

06/25/20 BofA
Genfit's NASH program 'all but done,' says BofA, initiating with an Underperform
06/25/20 BofA
Genfit initiated with an Underperform at BofA
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

  • 11
    Dec
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

GNFT Genfit
$5.57 /

-0.42 (-7.01%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

Over a week ago
Conference/Events
CymaBay management to meet virtually with Cantor Fitzgerald » 04:55
06/25/20
06/25
04:55
06/25/20
04:55
CBAY

CymaBay

$3.75 /

-0.165 (-4.22%)

Virtual Meeting to be…

Virtual Meeting to be held on June 25 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
CBAY CymaBay
$3.75 /

-0.165 (-4.22%)

CBAY CymaBay
$3.75 /

-0.165 (-4.22%)

06/22/20 B. Riley FBR
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR
05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
CBAY CymaBay
$3.75 /

-0.165 (-4.22%)

CBAY CymaBay
$3.75 /

-0.165 (-4.22%)

CBAY CymaBay
$3.75 /

-0.165 (-4.22%)

Conference/Events
CymaBay management to meet virtually with Cantor Fitzgerald » 08:55
06/23/20
06/23
08:55
06/23/20
08:55
CBAY

CymaBay

$4.13 /

+0.15 (+3.77%)

Virtual Meeting to be…

Virtual Meeting to be held on June 25 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
CBAY CymaBay
$4.13 /

+0.15 (+3.77%)

CBAY CymaBay
$4.13 /

+0.15 (+3.77%)

06/22/20 B. Riley FBR
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR
05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
CBAY CymaBay
$4.13 /

+0.15 (+3.77%)

CBAY CymaBay
$4.13 /

+0.15 (+3.77%)

CBAY CymaBay
$4.13 /

+0.15 (+3.77%)

Recommendations
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR » 08:41
06/22/20
06/22
08:41
06/22/20
08:41
CBAY

CymaBay

$3.98 /

+0.3 (+8.15%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani reiterates a Buy rating on CymaBay Therapeutics with a $6 price target after the company presented new data from the previously completed open label Phase II study of seladelpar in primary biliary cholangitis patients as part of the Digestive Disease Week Online Education program. Strong efficacy was reaffirmed across a variety of measures of pruritus, but seladelpar's ongoing safety review remains the key driver to the investment thesis, Mamtani tells investors in a research note. The analyst sees a favorable risk/reward going into upcoming FDA multi-step engagement in Q3.

ShowHide Related Items >><<
CBAY CymaBay
$3.98 /

+0.3 (+8.15%)

CBAY CymaBay
$3.98 /

+0.3 (+8.15%)

05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
05/12/20
Fly Intel: Top five analyst upgrades
CBAY CymaBay
$3.98 /

+0.3 (+8.15%)

CBAY CymaBay
$3.98 /

+0.3 (+8.15%)

CBAY CymaBay
$3.98 /

+0.3 (+8.15%)

Hot Stocks
CymaBay presents data from Phase 2 study of seladelpar in PBC » 08:05
06/19/20
06/19
08:05
06/19/20
08:05
CBAY

CymaBay

$3.68 /

-0.02 (-0.54%)

CymaBay Therapeutics…

CymaBay Therapeutics announced new data from a previously completed open-label Phase 2 study of seladelpar in patients with primary biliary cholangitis. These data were made available as an electronic presentation through the Digestive Disease Week 2020 Online Education program. Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta that has demonstrated anti-cholestatic and anti-inflammatory effects in clinical studies for PBC. The electronic presentation titled "Effects on Pruritus and Sleep Disturbance in Patients with Primary Biliary Cholangitis after 1 year of Treatment with Seladelpar, a Peroxisome Proliferator-Activated Receptor Delta Agonist: Results of an Open-Label Phase 2 Study," highlights the effect of seladelpar treatment over one year on key patient reported measures of pruritus and quality of life. PBC patients with an incomplete response or intolerance to ursodeoxycholic acid were randomized in this study to either seladelpar 2 mg, 5/10 mg or 10 mg groups and treated for 1yr. Pruritus and QoL measures were evaluated at baseline through 1yr for patients in the 5/10 mg and 10 mg groups using visual analogue scale, 5D-itch scale and PBC-40 questionnaires. Substantial improvement in pruritus at 1yr in patients with moderate to severe pruritus was seen in 58% and 93% of patients in the 5/10 mg and 10 mg groups, respectively. About half of the patients experienced BL sleep disturbance due to itch as measured by the 5-D itch score. Of these patients, improvement in sleep disturbance at 1yr was observed in 81% and 78% of patients. A consistent pattern of improvements in PBC-40 itch, sleep and fatigue were noted.

ShowHide Related Items >><<
CBAY CymaBay
$3.68 /

-0.02 (-0.54%)

CBAY CymaBay
$3.68 /

-0.02 (-0.54%)

05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
05/12/20
Fly Intel: Top five analyst upgrades
CBAY CymaBay
$3.68 /

-0.02 (-0.54%)

CBAY CymaBay
$3.68 /

-0.02 (-0.54%)

CBAY CymaBay
$3.68 /

-0.02 (-0.54%)

Options
Unusual call flow in option market yesterday » 07:35
06/16/20
06/16
07:35
06/16/20
07:35
MRVL

Marvell

$34.40 /

+0.69 (+2.05%)

, CBAY

CymaBay

$3.91 /

+0.37 (+10.45%)

Notable call activity was…

Notable call activity was cited Monday in Marvell (MRVL) and CymaBay (CBAY).

ShowHide Related Items >><<
MRVL Marvell
$34.40 /

+0.69 (+2.05%)

CBAY CymaBay
$3.91 /

+0.37 (+10.45%)

MRVL Marvell
$34.40 /

+0.69 (+2.05%)

05/29/20 Susquehanna
Marvell delivered results beyond expectations, says Susquehanna
05/29/20 JPMorgan
Marvell price target raised to $36 from $31 at JPMorgan
05/29/20 Needham
Marvell price target raised to $34 from $28 at Needham
05/29/20 Rosenblatt
Marvell price target raised to $42 from $32 at Rosenblatt
CBAY CymaBay
$3.91 /

+0.37 (+10.45%)

05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
05/12/20
Fly Intel: Top five analyst upgrades
MRVL Marvell
$34.40 /

+0.69 (+2.05%)

CBAY CymaBay
$3.91 /

+0.37 (+10.45%)

MRVL Marvell
$34.40 /

+0.69 (+2.05%)

MRVL Marvell
$34.40 /

+0.69 (+2.05%)

CBAY CymaBay
$3.91 /

+0.37 (+10.45%)

MRVL Marvell
$34.40 /

+0.69 (+2.05%)

CBAY CymaBay
$3.91 /

+0.37 (+10.45%)

Options
Cymabay calls lead puts 20:1 as shares lift 10% and implied volatility » 14:26
06/15/20
06/15
14:26
06/15/20
14:26
CBAY

CymaBay

$3.93 /

+0.39 (+11.02%)

Cymabay calls lead puts…

Cymabay calls lead puts 20:1 as shares lift 10% and implied volatility increases. Stock up 38c this afternoon ner $3.92 with 2200 calls trading vs 113 puts and July 5 calls dominating the flow, with 1855 contracts trading from 20 to 55c. Largest blocks printed as auctions on the ISE just before 12:40ET when shares were $3.90. CBAY shares nearly doubled last month from the 1.80 level following on headlines regarding the company's seladelpar drug for liver disease.

ShowHide Related Items >><<
CBAY CymaBay
$3.93 /

+0.39 (+11.02%)

CBAY CymaBay
$3.93 /

+0.39 (+11.02%)

05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
05/12/20
Fly Intel: Top five analyst upgrades
CBAY CymaBay
$3.93 /

+0.39 (+11.02%)

CBAY CymaBay
$3.93 /

+0.39 (+11.02%)

CBAY CymaBay
$3.93 /

+0.39 (+11.02%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.